Lapchak Paul A
UCSD Neuroscience MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA.
Curr Opin Investig Drugs. 2002 Dec;3(12):1758-62.
Centaur and AstraZeneca are developing NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, free radical trapping agent, for the potential therapy of reperfusion injury following stroke. Phase II clinical trials are ongoing, with phase III trials in acute stroke planned for initiation in early 2003.
半人马公司和阿斯利康公司正在研发NXY - 059，一种α - 苯基 - N - 叔丁基硝酮衍生物，自由基捕获剂，用于中风后再灌注损伤的潜在治疗。II期临床试验正在进行中，急性中风的III期试验计划于2003年初启动。
